Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : email@example.com
BI-1347 inhibits CDK8 and CDK19, which leads to reduced levels of phosphorylated Stat1 and increased activity of NK cells, potentially resulting in tumor growth inhibition, in combination with other agents (PMID: 32024684, PMID: 36398965).
|DrugClasses||CDK8 Inhibitor 5|
|CAS Registry Number||NA|
|Therapy Name||Drugs||Efficacy Evidence||Clinical Trials|
|BI-1347 + Selumetinib||BI-1347 Selumetinib||1||0|
|BI-1347 + Trametinib||BI-1347 Trametinib||1||0|